English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objectives:  In obese patients the superficial adipose tissue expresses cytokines, and sirtuins, that may affect myocardial function. In this study, we investigated the effect of metformin therapy added to a hypocaloric diet on the inflammatory pattern and cardiac performance (MPI) in obese patients with pre-diabetic condition.   Materials and Methods:  Fifty-eight obese patients that were enrolled for abdominoplastic surgery were divided into patients with pre-diabetic condition (n 40) and normo-glycemic patients (n18). Patients with pre-diabetic condition were randomly assigned to metformin therapy added to a hypocaloric diet (group 1, n 20) or to a hypocaloric diet therapy alone (group 2, n20). Patients with normo-glycemic condition were assigned to a hypocaloric diet therapy.   Results:  During enrollment, obese patients with a pre-diabetic condition (group 1 and 2) presented higher glucose values, lower values of insulin, and higher values of the homeostasis model for the assessment of insulin resistance (HOMA-IR) than obese patients with normo-glycemic condition(group 3). In addition, they had higher values of C Reactive protein (CRP), interleukin 6 (IL6), and lower values of sirtuin 1(SIRT1). In the 12th month of the follow-up, metformin therapy induced in patients with pre-diabetic condition (group 1) a significant reduction of glucose values, HOMA-IR, and inflammatory markers such as CRP (1.04 ± 0.48 vs. 0.49 ± 0.02 mmol/L,  p  < 0.05), IL6 (4.22 ± 0.45 vs. 3.33 ± 0.34 pg/ml,  p  < 0.05), TNFα (6.95 ± 0.59 vs. 5.15 ± 0.44 pg/ml,  p  < 0.05), and Nitrotyrosine (5,214 ± 0,702 vs. 2,151 ± 0,351 nmol/l,  p  < 0.05). This was associated with a significant reduction of Intima-media thickness (1.01 ± 0.15 vs. 0.86 ± 0.15 mm,  p  < 0.05), Septum (14 ± 2.5 vs. 10.5 ± 2 mm,  p  < 0.05), Posterior wall (11 ± 1.5 vs. 8 ± 1 mm,  p  < 0.05), LV mass (192.5 ± 49.5 vs. 133.2 ± 37.6 g,  p  < 0.05) and of MPI (0.58 ± 0.03 vs. 0.38 ± 0.02,  p  < 0.05). At 12 months of follow-up, group 2 experienced only a reduction of cholesterol (4.15 ± 0.94 vs. 4.51 ± 0.88 mmol/L,  p  < 0.05) and triglycerides (1.71 ± 1.18 vs. 1.83 ± 0.54 mmol/L,  p  < 0.05). At 12 months of follow-up, group 3 experienced a significant reduction of inflammatory markers, and also of echographic parameters, associated with amelioration of myocardial performance. To date, IL6 expression was related to higher values of left ventricle mass ( R -value 0.272,  p -value 0.039), and to higher IMT ( R -value 0.272,  p -value 0.039), such as those observed for CRP ( R -value 0.308,  p -value 0.021), for glucose blood values ( R -value 0.449,  p -value 0.001), and for HOMA-IR ( R -value 0.366,  p -value 0.005). An inverse correlation was found between subcutaneous fat expression of SIRT1 and myocardial performance index ( R -value−0.236,  p -value 0.002).   Conclusion:  In obese patients with pre-diabetic condition a metformin therapy may reduce inflammation and oxidative stress, and this may be associated with the amelioration of the cardiac performance.  Clinical research trial number: NCT03439592.

Inflammatory Cytokines and SIRT1 Levels in Subcutaneous Abdominal Fat: Relationship With Cardiac Performance in Overweight Pre-diabetics Patients